文献速递膀胱癌与上尿路尿路上皮癌

Infigratinib 治疗 FGFR3 改变晚期尿路上皮癌中高磷血症与抗肿瘤疗效相关

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
PubMed 文献 · Eur Urol · 2020-08-23

该研究回顾性分析 67 例铂类难治性 FGFR3 改变转移性尿路上皮癌患者,接受口服 Infigratinib 125 mg/d 治疗。48 例(71.6%)出现高磷血症,高磷血症组客观缓解率为 33.3%,无高磷血症组为 5.3%,提示高磷血症可能是疗效的替代生物标志物。

要点

  • Infigratinib 治疗中 71.6% 患者出现高磷血症
  • 高磷血症组客观缓解率 33.3% 优于无高磷血症组 5.3%
  • 高磷血症可能作为 FGFR 抑制剂疗效的替代标志物

核心结论

  • Infigratinib 引起的高磷血症与 FGFR3 改变转移性尿路上皮癌患者的治疗反应相关,可能作为疗效替代生物标志物。

研究设计与样本

  • 回顾性分析 I 期试验中 67 例铂类难治性 FGFR3 改变转移性尿路上皮癌患者,口服 Infigratinib 125 mg/d,连用 21 天每 28 天重复。

主要发现

  • 67 例中 48 例(71.6%)出现高磷血症。
  • 高磷血症组客观缓解率 33.3%(95%CI 20.4-48.4),无高磷血症组 5.3%(95%CI 0.1-26.0)。
  • 高磷血症组疾病控制率 75.0%(95%CI 60.4-86.4),无高磷血症组 36.8%(95%CI 16.3-61.6)。
  • 1 个月界标分析中该趋势保持不变。
  • 药代动力学/药效学分析显示血清磷水平与 Infigratinib 生理浓度呈正相关。

临床怎么用

  • 在 Infigratinib 治疗 FGFR3 改变转移性尿路上皮癌时,监测血清磷水平可能有助于预判疗效。

局限性

  • 回顾性设计,无对照组,样本量有限。
  • 结果需在更大规模前瞻性试验中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infigratinib (BGJ398) is a potent, selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor with significant activity in metastatic urothelial carcinoma (mUC) bearing FGFR3 alterations. It can cause hyperphosphatemia due to the "on-target" class effect of FGFR1 inhibition. OBJECTIVE: To investigate the relationship between hyperphosphatemia and treatment response in patients with mUC. INTERVENTION: Oral infigratinib 125 mg/d for 21 d every 28 d. DESIGN, SETTING, AND PARTICIPANTS: Data from patients treated with infigratinib in a phase I trial with platinum-refractory mUC and activating FGFR3 alterations were retrospectively analyzed for clinical efficacy in relation to serum hyperphosphatemia. The relationship between plasma infigratinib concentration and phosphorous levels was also assessed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinical outcomes were compared in groups with/without hyperphosphatemia. RESULTS AND LIMITATIONS: Of the 67 patients enrolled, 48 (71.6%) had hyperphosphatemia on one or more laboratory tests. Findings in patients with versus without hyperphosphatemia were the following: overall response rate 33.3% (95% confidence interval [CI] 20.4-48.4) versus 5.3% (95% CI 0.1-26.0); disease control rate 75.0% (95% CI 60.4-86.4) versus 36.8% (95% CI 16.3-61.6). This trend was maintained in a 1-mo landmark analysis. Pharmacokinetic/pharmacodynamic analysis showed that serum phosphorus levels and physiologic infigratinib concentrations were correlated positively. Key limitations include retrospective design, lack of comparator, and limited sample size. CONCLUSIONS: This is the first published study to suggest that hyperphosphatemia caused by FGFR inhibitors, such as infigratinib, can be a surrogate biomarker for treatment response. These findings are consistent with other reported observations and will need to be validated further in a larger prospective trial. PATIENT SUMMARY: Targeted therapy is a new paradigm in treating bladder cancer. In a study using infigratinib, a drug that targets mutations in a gene called fibroblast growth factor receptor 3 (FGFR3), we found that elevated levels of phosphorous were associated with greater clinical benefit. In the future, these data may help inform treatment strategies.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lyou Y, Grivas P, Rosenberg JE, et al. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. Eur Urol. 2020. PMID: 32847703. doi:10.1016/j.eururo.2020.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。